OCS Reduction According to the Presence of Nasal Polyps or Atopic Status in the PONENTE Study by Heaney, Liam G et al.
1 
 
OCS Reduction According to the Presence of Nasal Polyps or Atopic Status in the 
PONENTE Study 
 
Authors: Liam G. Heaney1; Andrew Menzies-Gow2; Mark Gurnell3; Jonathan Corren4; 
Elisabeth H. Bel5; Jorge Maspero6; Timothy Harrison7,8; David Jackson9,10; David Price11,12; 
Njira Lugogo13; James Kreindler14; Annie Burden15; Alex de Giorgio Miller16; Kelly Padilla17; 
Ubaldo J. Martin18; Esther Garcia Gil19 
 
1Centre for Experimental Medicine, Queen’s University Belfast, Belfast, UK; 2Royal Brompton 
& Harefield NHS Foundation Trust, London, UK; 3Wellcome-MRC Institute of Metabolic 
Science, Cambridge Biomedical Campus, Cambridge, UK; 4David Geffen School of Medicine at 
UCLA and Allergy Medical Clinic Inc., Los Angeles, CA, USA; 5Amsterdam UMC, University 
of Amsterdam, Amsterdam, The Netherlands; 6Fundación CIDEA, Buenos Aires, Argentina; 
7Nottingham Respiratory NIHR BRC, University of Nottingham, UK; 8BioPharmaceuticals 
R&D Digital, AstraZeneca, Cambridge, UK; 9Guy's Severe Asthma Center, Guy’s & St. 
Thomas’ NHS Trust, London, UK; 10Asthma UK Centre, School of Immunology & Microbial 
Sciences, King's College London, London, UK; 11Observational and Pragmatic Research 
Institute, Singapore; 12Centre of Academic Primary Care, Division of Applied Health Sciences, 
University of Aberdeen, Aberdeen, United Kingdom;13University of Michigan Medical Center, 
Ann Arbor, MI, USA; 14Global Medical Respiratory, BioPharmaceuticals Medical, AstraZeneca, 
Wilmington, DE; USA; 15BioPharmaceuticals R&D, Late Respiratory & Immunology, 
Biometrics, AstraZeneca, Cambridge, UK; 16Medical & Scientific Affairs, BioPharmaceuticals 
Medical, AstraZeneca, Luton, UK; 17Late Respiratory & Immunology, BioPharmaceuticals 
R&D, AstraZeneca, Durham, NC, USA; 18Late Stage Development, Respiratory and 
Immunology Therapeutic Area, AstraZeneca, Gaithersburg, MD, USA; 19Global Medical 
Respiratory, BioPharmaceuticals Medical, AstraZeneca, Barcelona, Spain 
 
 
Rationale: Severe asthma is frequently associated with comorbidities. Nasal polyps (NP), in 
particular, indicate an eosinophilic phenotype and have been shown to predict an enhanced 
response to benralizumab in terms of asthma exacerbations and lung function. Increased serum 
immunoglobulin (Ig) E levels and atopy are also common in severe asthma, although they tend 
not to be associated with increased risk of exacerbations or predict response to biologics. 
Benralizumab has been shown to decrease long-term oral corticosteroid (OCS) use among 
patients with severe asthma, but whether the presence of comorbid NP, elevated serum IgE, or 




Methods: An analysis of 598 patients in the multicenter, open-label phase IIIb PONENTE trial 
was conducted to demonstrate the ability of benralizumab to eliminate or reduce the daily OCS 
dosage according to the presence of comorbidities before a personalized, variable OCS down-
titration was initiated. Endpoints included the proportion of patients eliminating OCS use, the 
proportion achieving a dosage ≤5 mg if adrenal insufficiency was the cause of stopping the OCS 
taper, and the proportion achieving a dosage ≤5 mg regardless of the cause of stopping the OCS 
taper. 
Results: At baseline, 20.9% of patients had nasal polyps, the median IgE level was 130.7 (range, 
1.5–17840.7) IU/mL, and 47.2% were atopic with positive Phadiatop results to common 
aeroallergens. More patients without chronic rhinosinusitis (CRS) than with CRS achieved the 
endpoints. Of patients with CRS, a higher proportion of those with NP than without NP achieved 
the endpoints. Similar proportions of atopic and non-atopic patients, as well as of patients with 
different IgE levels, achieved OCS elimination or a daily dosage ≤5 mg. A greater proportion of 
atopic patients achieved OCS elimination than non-atopic patients, but no difference was 
observed among patients with different IgE levels (Table). 
Conclusions: Most patients achieved elimination or lowest possible daily OCS dosage 
irrespective of baseline atopic status or IgE levels. Among those with CRS, more patients with 





Table. Endpoints according to patient comorbidity subgroups 
Endpoint Patients eliminating OCS, 
n (%) 
(95% CI) 
Patients achieving daily 
OCS dosage ≤5 mg if AI 
was the cause of stopping 
the taper, n (%) 
(95% CI) 
Patients achieving daily 
OCS dosage ≤5 mg 
regardless of the cause of 
stopping the taper, n (%) 
(95% CI) 
Patients achieving 
>0% reduction in OCS 
dosage, n (%) 
(95% CI) 
Patient subgroup     
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